The share repurchase is a routine execution of GSK's announced buyback program and does not signal any change in strategy. Traders should monitor for larger cumulative buyback volumes over time rather than reacting to individual daily transactions.
GSK drugs
GSK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $58.94entry
- T+1 · 7mo ago +0.41%α −0.80% · $59.18
- T+5 · 7mo ago −2.70%α −5.99% · $57.35
- T+20 · 6mo ago −15.49%α −23.22% · $49.81
- T+60 · 4mo ago −10.89%α −19.82% · $52.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weighted average price of 2,182.28 GBp. This transaction increases the company's treasury shares to 258.1 million, representing 6.36% of voting rights.
Key Facts
- GSK repurchased 325,000 ordinary shares on April 10, 2026
- Purchase price ranged from 2,157.00p to 2,196.00p per share, with a volume-weighted average of 2,182.28p
- Shares were purchased through BNP Paribas SA on multiple exchanges
- Total treasury shares now stand at 258,112,615, or 6.36% of voting rights
- The repurchase is part of an existing buyback program announced on February 17, 2026
Financial Impact
The repurchase represents a nominal investment of approximately £709 million (325,000 shares × 2,182.28 GBp), though the exact amount is not disclosed in the filing.
Risk Factors
- The buyback could accelerate if the company has excess cash, potentially reducing capital available for R&D or acquisitions
- Continued repurchases may limit downside protection if the stock price declines
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003420 |
| Document: 0001654954-26-003420-index-headers.html | 0001654954-26-003420 |
| Document: 0001654954-26-003420-index.html | 0001654954-26-003420 |
| Document: 0001654954-26-003420.txt | 0001654954-26-003420 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers